Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A1 | O00337 | 1/20 | 0.39 |
| ▸ | ADK | P55263 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.37 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.37 |
| ▸ | SLC29A1 | Q99808 | 6/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | GLA | P06280 | 1/20 | 0.36 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | NPY1R | P25929 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPY2R | P49146 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4732508 | 0.85 | SLC29A1 (0.44) | SLC29A1TP53 | |
| SCHEMBL29493048 | 0.81 | TYMP (0.44) | ADORA3LMNAALDH1A1MAPK1 | |
| SCHEMBL27220667 | 0.80 | SLC28A1 (0.42) | SLC28A1ADORA3ADORA2ASLC29A1SMN1; SMN2 | |
| SCHEMBL28092439 | 0.80 | SLC28A1 (0.42) | SLC28A1ADORA3ADORA2ASLC29A1SMN1; SMN2 | |
| SCHEMBL29406372 | 0.80 | SLC28A1 (0.42) | SLC28A1ADORA3ADORA2ASLC29A1SMN1; SMN2 | |
| SCHEMBL444963 | 0.80 | SLC28A1 (0.42) | SLC28A1ADORA3ADORA2A | |
| SCHEMBL28042204 | 0.77 | SLC28A1 (0.39) | SLC28A1ADORA3ADORA2ASLC29A1SMN1; SMN2 | |
| SCHEMBL4783231 | 0.76 | SLC28A1 (0.39) | SLC28A1ADORA3ADORA2ASLC29A1 | |
| SCHEMBL31186229 | 0.75 | SLC28A1 (0.38) | SLC28A1ADORA3ADORA2ASLC29A1LMNA | |
| SCHEMBL1140712 | 0.74 | ADORA3 (0.43) | ADKADORA3ADORA2ASLC29A1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 168 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12037583-B2 | Compositions and methods for immunooncology | NOVARTIS AG (CH) | 2024-07-16 | — | — | US | disclosed |
| EP-4372090-A2 | CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING GRNAS | Editas Medicine, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| EP-3215617-B1 | SYSTEMS FOR IMPROVING CRISPR/CAS-MEDIATED GENOME-EDITING | EDITAS MEDICINE INC (US) | 2024-05-08 | — | — | EP | disclosed |
| EP-4359527-A2 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | Novartis AG (CH) | 2024-05-01 | — | — | EP | disclosed |
| US-20240132877-A1 | GENOME EDITING SYSTEMS COMPRISING REPAIR-MODULATING ENZYME MOLECULES AND METHODS OF THEIR USE | EDITAS MEDICINE, INC. | 2024-04-25 | — | — | US | disclosed |
| US-20240110179-A1 | SYSTEMS AND METHODS FOR TREATING ALPHA 1-ANTITRYPSIN (A1AT) DEFICIENCY | EDITAS MEDICINE, INC. (US) | 2024-04-04 | — | — | US | disclosed |
| US-20240067992-A1 | HUMAN HEMATOPOIETIC STEM CELL HAVING A MODIFIED BCL11A GENE AND METHODS OF MAKING THE CELL | EDITAS MEDICINE, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| US-11911415-B2 | CRISPR/Cas-related methods and compositions for improving transplantation | EDITAS MEDICINE, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20240002843-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | NOVARTIS AG (CH) | 2024-01-04 | — | — | US | disclosed |
| EP-3363903-B1 | CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING GRNAS | EDITAS MEDICINE INC (US) | 2024-01-03 | — | — | EP | disclosed |
| WO-2015148863-A2 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING SICKLE CELL DISEASE | EDITAS MEDICINE, INC. (US) | 2015-10-01 | — | — | WO | disclosed |
| WO-2015148670-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING HIV INFECTION AND AIDS | EDITAS MEDICINE INC. (US) | 2015-10-01 | — | — | WO | disclosed |
| WO-2015138510-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING LEBER'S CONGENITAL AMAUROSIS 10 (LCA10) | EDITAS MEDICINE., INC. (US) | 2015-09-17 | — | — | WO | disclosed |
| WO-2015134812-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING USHER SYNDROME AND RETINITIS PIGMENTOSA | EDITAS MEDICINE, INC. (US) | 2015-09-11 | — | — | WO | disclosed |
| US-20150252358-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING LEBER'S CONGENITAL AMAUROSIS 10 (LCA10) | EDITAS MEDICINE, INC. | 2015-09-10 | — | — | US | disclosed |
| US-20150232881-A1 | CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS | EDITAS MEDICINE, INC. (US) | 2015-08-20 | — | — | US | disclosed |
| WO-2015070083-A1 | CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS | EDITAS MEDICINE,INC. (US) | 2015-05-14 | — | — | WO | disclosed |
| WO-2015048577-A2 | CRISPR-RELATED METHODS AND COMPOSITIONS | EDITAS MEDICINE, INC. (US) | 2015-04-02 | — | — | WO | disclosed |
| US-6627456-B1 | Incorporating into the oligonucleotide analogs that are the components of a library to which in vitro selection methods functionalized standard and non-standard nucleotides, and incorporating functionalized cofactors into the experiment | BENNER, STEVEN | 2003-09-30 | — | — | US | disclosed |
| US-6312897-B1 | RELATES TO TECHNIQUE FOR INHIBITING PROTEIN-ADENINE NONCOVALENT CONTACTS WITHOUT DISRUPTING SECONDARY STRUCTURE OF DNA, THEREBY PROVIDING TEMPLATE-DIRECTED INTERFERENCE TECHNIQUE FOR PRECISELY STUDYING PROTEIN-DNA INTERACTIONS | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2001-11-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11911415-B2 | CRISPR/Cas-related methods and compositions for improving transplantation | HLA-C, HLA-DRB1, HLA-B | SLC28A1 1852/4885ADK 3287/4885ADORA3 3662/4885 |
| US-20150252358-A1 | CRISPR/CAS-RELATED METHODS AND COMPOSITIONS FOR TREATING LEBER'S CONGENITAL AMAUROSIS 10 (LCA10) | CHLSN, CLN6, NAA10 | SLC28A1 3586/4885ADK 2121/4885ADORA3 2810/4885 |
| US-20240002843-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES | HBG2, HBB, HBG1 | SLC28A1 2492/4885ADK 1596/4885ADORA3 1950/4885 |
| US-20240067992-A1 | HUMAN HEMATOPOIETIC STEM CELL HAVING A MODIFIED BCL11A GENE AND METHODS OF MAKING THE CELL | MCL1, BCL2L11, BCL2L13 | SLC28A1 2740/4885ADK 3237/4885ADORA3 3683/4885 |
| US-20240132877-A1 | GENOME EDITING SYSTEMS COMPRISING REPAIR-MODULATING ENZYME MOLECULES AND METHODS OF THEIR USE | DCLRE1B, MPG, UNG | SLC28A1 4259/4885ADK 1097/4885ADORA3 3421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.